Protein space race continues

Two recent deals by Ablynx N.V. illustrate the ongoing rush by big pharma companies to make sure they are players in the next-generation antibody/protein space.

In the past two weeks, Ablynx has signed deals covering therapeutic applications of its Nanobody platform with Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and Centocor Research & Development Inc. (Malvern, Penn.), a subsidiary of

Read the full 586 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE